

The Medical Letter[®]

on Drugs and Therapeutics

Volume 65

January 23, 2023

ISSUE No.
1668

IN THIS ISSUE

In Brief: *Furoscix* – A Subcutaneous Furosemide Infusor for Heart Failure.....p 14

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 65 (Issue 1668)

January 23, 2023

Take CME Exams

IN BRIEF

***Furoscix* – A Subcutaneous Furosemide Infusor for Heart Failure**

The FDA has approved *Furoscix* (scPharmaceuticals), a subcutaneous formulation of the loop diuretic furosemide administered via a single-use, on-body infusor, for treatment of congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II-III chronic heart failure (HF). Furosemide (*Lasix*, and generics) has been available for years in oral and IV formulations.

Pronunciation and Abbreviation Key

Furosemide: fure oh' se mide *Furoscix*: fue roe' six
HF: heart failure

DIURETICS IN HF – Diuretics can reduce fluid retention in patients with HF, but their effect on survival is unclear. Loop diuretics such as furosemide, bumetanide, and torsemide are more effective than thiazide-type diuretics, such as hydrochlorothiazide, for this indication. Intravenous administration of loop diuretics is often used to achieve rapid diuresis in acute decompensation or to overcome diuretic resistance.¹

EFFICACY AND SAFETY – FDA approval of the of the new formulation was based on the results of a study demonstrating that the bioavailability of *Furoscix* (30 mg SC infusion over 1 hour, followed by 12.5 mg/hour for the next 4 hours) was 99.6% relative to IV furosemide (two 40-mg bolus doses separated by 2 hours) and that it produced equivalent diuresis.² The most common adverse effects with the SC infusion were administration-site erythema, bruising, edema, and pain.

An unpublished trial (FREEDOM-HF) in 24 patients presenting to the emergency department with worsening NYHA Class II or III HF compared outpatient use of *Furoscix* to hospital admission for IV diuresis in

66 matched controls. According to the manufacturer, no patients in the *Furoscix* group required an initial heart failure hospital admission and 96% of *Furoscix*-treated patients remained out of the hospital for 30 days after treatment. HF-associated healthcare costs were significantly lower in the *Furoscix* group.³

DOSAGE, ADMINISTRATION, AND COST – *Furoscix* should not be used for emergency situations or in patients with acute pulmonary edema. It is also not indicated for chronic use; patients should be switched to oral diuretic therapy as soon as practical.

Furoscix is supplied as a single-use, subcutaneous on-body infusor copackaged with a prefilled cartridge containing an 80 mg/10 mL pH neutral solution of furosemide. The device is pre-programmed to deliver a total of 80 mg of furosemide (30 mg over the first hour, followed by 12.5 mg per hour for the subsequent 4 hours).

After loading the prefilled cartridge into the infusor, the patient should place the device on an area of clean, dry skin on either side of the navel. Pressing the start button on the infusor initiates the subcutaneous infusion. Activity should be limited for the duration of the infusion. The on-body infusor should be kept dry and should not be used within 12 inches of mobile phones, tablets, computers, or wireless accessories. The approximate cost for one on-body infusor and prefilled cartridge is \$822.⁴ ■

1. Drugs for chronic heart failure. *Med Lett Drugs Ther* 2021; 63:89.
2. DA Sica et al. Subcutaneous furosemide in heart failure: pharmacokinetic characteristics of a newly buffered solution. *JACC Basic Transl Sci* 2018; 3:25.
3. NIH. *Furoscix* real-world evaluation for decreasing hospital admissions in heart failure (FREEDOM-HF). Available at: <https://bit.ly/3HhsW2M>. Accessed January 5, 2023.
4. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: Analysource® Monthly. January 5, 2023. Reprinted with permission by First Databank, Inc. All rights reserved. ©2023. www.fdbhealth.com/policies/drug-pricing-policy.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli
EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer. The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:
The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:
Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:
To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):
1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:
E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:    

Copyright 2023. ISSN 1523-2859

